Congratulations to @chaidiscovery on its $400M Series C. Chai treats medicine design as an engineering problem, one that can be solved with precision, speed, and scale. Eli Lilly, Pfizer, and Novartis are running its generative design suite, including the latest model Chai-3, against drug targets that have defeated traditional discovery methods. We co-led Chai's Series B, and we're proud to keep backing @joshim5, @jackdent, @Mattmcpartlon1, @j_boitreaud, and the entire team.